Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Pharma & Drugs
Share your love
Top 5 Milestones in Ophthalmology History
In this article, we explore five significant milestones in the history of ophthalmology that have shaped the way we approach eye health and treatment. The ancient Egyptians, known for their advanced civilization and remarkable contributions to various fields, including medicine,…
FDA Calls for Study on Aldeyra’s Reproxalap in DED
Aldeyra Therapeutics announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) in response to the New Drug Application (NDA) for reproxalap, an investigational drug candidate designed for the treatment of dry eye disease.…
Reviving Hope for Amblyopia: Late-Stage Treatment
In children with amblyopia, often referred to as “lazy eye,” one eye exhibits weaker vision than the other due to various factors. This weaker eye may struggle with focusing, misalignment due to strabismus, or vision obstruction from conditions like cataracts…
New Experimental Drug Shows Promise in Treating DME
A recent study published in Nature Medicine has unveiled promising insights into a potential breakthrough in the treatment of Diabetic Macular Edema (DME). The study suggests that an experimental drug, part of a new class of therapeutics called “senolytics,” could…
Treatment of Intraocular Melanoma | OBN
Melanoma of the uveal tract (iris, ciliary body, and choroid), though rare, is the most common primary intraocular malignancy in adults. The mean age-adjusted incidence of uveal melanoma in the United States is approximately 4.3 new cases per million people,…
4DMT Reports Positive Interim Data for Wet AMD Treatment
4D Molecular Therapeutics (4DMT) announced positive interim data from the Phase 2 PRISM clinical trial, marking a significant stride in the treatment of wet age-related macular degeneration (wet AMD). Arshad M. Khanani, MD, MA, FASRS, presented the data at the…
Mireca Medicines Gets $1M Boost for Retinal Disease Treatment
Mireca Medicines has been awarded a $989,000 ‘Translational Research Acceleration Program Award’ from the Foundation Fighting Blindness, enabling the company to advance preclinical development of its lead product, MM238. Recognizing Mireca’s pivotal role in targeting the cGMP pathway for treating…
Formosa & Cristália Partner for APP13007 Rights in Brazil
Formosa Pharmaceuticals announced a strategic licensing agreement with Cristália Produtos Químicos Farmacêuticos to secure exclusive commercialization rights for APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) in Brazil. APP13007 is designed for the treatment of inflammation and pain following ocular surgery and…
FDA Approves Modified Axpaxli Trial by Ocular Therapeutix
Ocular Therapeutix announced that the FDA has granted approval for a modification to the special protocol assessment (SPA) agreement for the pivotal phase 3 SOL clinical trial of Axpaxli (axitinib intravitreal implant, also known as OTX-TKI). This modification marks a…
Hearing Loss is Rare in Tepezza Treatment for TED
A recent study, led by Dr. Raymond Douglas, MD, PhD, revealed that long-term hearing loss is a rare occurrence in individuals with normal audiometry at baseline following treatment with Tepezza [teprotumumab]. Published in the current issue of the prestigious journal…